Cann assumed coverage on shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) in a research report sent to investors on Monday morning. The brokerage issued an outperform rating and a $28.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on SYRS. HC Wainwright restated a hold rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a report on Friday, September 9th. Zacks Investment Research cut shares of Syros Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, September 22nd. Piper Jaffray Cos. restated a buy rating and set a $20.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, September 22nd. Finally, Wedbush restated an outperform rating and set a $18.00 price target on shares of Syros Pharmaceuticals in a report on Monday, November 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Syros Pharmaceuticals has an average rating of Buy and an average target price of $19.60.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.33 on Monday. The stock’s 50 day moving average price is $13.48 and its 200 day moving average price is $13.08. Syros Pharmaceuticals has a 12-month low of $8.16 and a 12-month high of $21.50. The company’s market capitalization is $311.66 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.11. On average, equities research analysts anticipate that Syros Pharmaceuticals will post ($4.03) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and republished in violation of US & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/29/syros-pharmaceuticals-inc-syrs-coverage-initiated-by-analysts-at-cann.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of SYRS. California State Teachers Retirement System acquired a new position in Syros Pharmaceuticals during the third quarter valued at about $137,000. Spark Investment Management LLC acquired a new position in Syros Pharmaceuticals during the third quarter valued at about $160,000. Hamilton Lane Advisors LLC acquired a new position in Syros Pharmaceuticals during the third quarter valued at about $193,000. Morgan Stanley acquired a new position in Syros Pharmaceuticals during the third quarter valued at about $469,000. Finally, AWM Investment Company Inc. acquired a new position in Syros Pharmaceuticals during the third quarter valued at about $660,000. 54.56% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.